Impact of the revised international prognostic scoring system cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: A retrospective multicenter study of the European society of blood and marrow transplantation

Haematologica

Volumn 100, Issue 3, 2015, Pages 400-408

  Koenecke, Christian ^a   Göhring, Gudrun ^a   de Wreede, Liesbeth C ^b,c   van Biezen, Anja ^b   Scheid, Christof ^d   Volin, Liisa ^e   Maertens, Johan ^f   Finke, Jürgen ^g   Schaap, Nicolaas ^h   Robin, Marie ⁱ   Passweg, Jakob ^j   Cornelissen, Jan ^k   Beelen, Dietrich ^l   Heuser, Michael ^a   de Witte, Theo ^h   Kröger, Nicolaus ^m  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c German Bone Marrow Donor Center   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF FREIBURG   (Germany)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j UNIVERSITY HOSPITAL BASEL   (Switzerland)

^k ERASMUS MEDICAL CENTER   (Netherlands)

^l UNIVERSITY HOSPITAL ESSEN   (Germany)

^m UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL FEATURE; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RISK FACTOR; STATISTICAL ANALYSIS; TREATMENT OUTCOME; ADOLESCENT; AGED; ALLOTRANSPLANTATION; BONE MARROW; CHROMOSOME ANALYSIS; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; EUROPE; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MEDICAL SOCIETY; METHODOLOGY; MONOSOMY; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW; CYTOGENETIC ANALYSIS; EUROPE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONOSOMY; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK; SOCIETIES, MEDICAL; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84926624472     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.116715     Document Type: Article

References (33)

1. de Witte T, Hagemeijer A, Suciu S, et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica. 2010;95(10):1754-1761.
2. Koreth J, Pidala J, Pérez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013; 31(21):2662-2670.
3. Kroger N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood. 2012; 119(24):5632-5639.
4. Kroger N, Bacher U, Bader P, et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biology of Blood and Marrow Transplantation. 2010; 16(9):1187-1211.
5. Alessandrino EP, Porta Della MG, Bacigalupo A, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 2008;112(3):895-902.
6. Runde V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998; 21(3):255-261.
7. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biology of Blood and Marrow Transplantation. 2008;14(4):458-468.
8. de Witte T, Suciu S, Verhoef G, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood. 2001; 98(8):2326-2331.
9. Nakai K, Kanda Y, Fukuhara S, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia. 2005;19(3):396-401.
10. Armand P, Kim HT, DeAngelo DJ, et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007;13(6):655-664
11. Armand P, Deeg HJ, Kim HT, et al. Multicenter validation study of a transplantation- specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant. 2010;45(5):877-885.
12. van Gelder M, de Wreede LC, Schetelig J, et al. Monosomal karyotype predicts poor survival after allogeneic stemcell transplantation in chromosome 7 abnormal myelodysplasticsyndrome and secondary acute myeloid leukemia. Leukemia. 2012; 20;27(4):879-888.
13. Deeg HJ, Scott BL, Fang M, et al. Five-group cytogenetic risk classification, monosomal karyotype and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. 2012; 16;120(7):1398-1408.
14. Porta Della MG, Alessandrino EP, Bacigalupo A, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014;10;123(15):2333-2342.
15. Yang Y-T, Hou H-A, Liu C-Y, et al. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients. Am J Hematol. 2014; 89(9):E142-49.
16. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.
17. Schanz J, Tuchler H, Sole F, et al. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. J Clin Oncol. 2012; 8;30(8):820-829.
18. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood. 2012; 120(12):2454-2465.
19. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-199.
20. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;30;114(5):937-951.
21. Iacobelli S. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2013;48 Suppl 1:S1-37.
22. Gray RJ. A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. Ann Stat. 1988;16;3: 1141-1154.
23. Verweij PJ, Van Houwelingen HC. Penalized likelihood in Cox regression. Stat Med. 1994;13(23-24):2427-2436.
24. Terry M. Therneau and Patricia M. Grambsch (2000). Modeling Survival Data: Extending the Cox Model. Springer, New York. ISBN 0-387-98784-3.
25. van Houwelingen H, Putter H. Dynamic Prediction in Clinical Survival Analysis. Boca Raton: CRC Press, 2011.
26. Nevill TJ, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 1998; 15;92(6):1910-1917.
27. Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011;20;29(15):1963-1970.
28. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;15;110(13): 4385-4395.
29. Van Besien K. Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program. Am Soci Hematol. 2013;(1):56-62.
30. Schroeder T, Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27(6): 1229-1235.
31. Yamazaki H, Suzuki M, Otsuki A, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 2014;25(4):415-427.
32. Bejar R, Stevenson KE, Caughey B, et al. Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2014; 32(25):2691-2698.
33. Onida F, Brand R, van Biezen A, et al. Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from Human Leukocyte Antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. Haematologica. 2014; 99(10):1582-1590